GT Biopharma Files 2024 Annual Report Amendment
Ticker: GTBP · Form: 10-K/A · Filed: Apr 14, 2025 · CIK: 109657
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
TL;DR
GT Biopharma filed its 2024 10-K amendment on 4/14/25. Check for updates.
AI Summary
GT Biopharma, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing was made on April 14, 2025, and it amends previous filings related to the company's operations and financial status. The company is incorporated in Delaware and its principal business is in Pharmaceutical Preparations.
Why It Matters
This amendment provides updated information for the fiscal year 2024, which is crucial for investors and stakeholders to assess the company's performance and financial health.
Risk Assessment
Risk Level: low — This filing is an amendment to a standard annual report and does not appear to contain significant new negative information.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending December 31, 2024.)
- 001-40023 — SEC File Number (Identifies the company's filings with the SEC.)
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- December 31, 2024 (date) — Fiscal Year End
- April 14, 2025 (date) — Filing Date
- Delaware (location) — State of Incorporation
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What specific changes or additions are made in this 10-K/A amendment compared to the original 10-K filing?
The filing is an amendment (10-K/A) to the annual report for the fiscal year ended December 31, 2024, indicating updates or corrections to the original filing, though the specific details of the changes are not provided in this header information.
What is the primary business of GT Biopharma, Inc. according to the filing?
GT Biopharma, Inc. is classified under Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When was this amendment filed with the SEC?
This amendment (10-K/A) was filed on April 14, 2025.
What was the fiscal year end date for the report being amended?
The fiscal year end date for the report being amended is December 31, 2024.
What is the company's state of incorporation?
GT Biopharma, Inc. is incorporated in Delaware.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 14, 2025 regarding GT Biopharma, Inc. (GTBP).